U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT07575893) titled 'CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma' on May 04.
Brief Summary: Patients with relapsed low-risk CD30 classical Hodgkin Lymphoma will have autologous CD30 CAR T-cell manufactured. Dose escalation will be used to determine the RP2D. Following lymphodepletion, CAR T-cell will be infused.
Study Start Date: Dec. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Classical Hodgkin Lymphoma
Intervention:
BIOLOGICAL: CD30+ CAR T-cells
patients with cHL with a good response following reinduction therapy will receive autologous CD30 CAR T-cells 1-14 days following lymphodepletion
DRUG: Bendamustin
Patients will...